POST-SURGICAL LIQUID BIOPSY - GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE PEGASUS TRIAL

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517704-10-00

Enrollment

156

Registered

2024-09-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon cancer

Brief summary

Number of post-surgery false negative cases after a double ctDNA-negative detection, defined as cases that become positive at subsequent interventional LB and/or that experience radiological relapse within 2 years.

Detailed description

Disease-Free Survival (DFS) at 2 and 3-years, Overall Survival (OS) at 5- years., Safety and tolerability according to CTCAE version 5.0., Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free at 2 and 3 years., Assessment of QLQ-C30 and CR-29 EORTC questionnaires.

Interventions

DRUGCAPECITABINE

DRUGOXALIPLATIN

DRUGFLUOROURACIL

DRUGIRINOTECAN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of post-surgery false negative cases after a double ctDNA-negative detection, defined as cases that become positive at subsequent interventional LB and/or that experience radiological relapse within 2 years.	—

Secondary

Measure	Time frame
Disease-Free Survival (DFS) at 2 and 3-years, Overall Survival (OS) at 5- years., Safety and tolerability according to CTCAE version 5.0., Number of patients experiencing ctDNA seroconversion (i.e. ctDNA+ that become ctDNA-) after any chemotherapy regimen remaining disease free at 2 and 3 years., Assessment of QLQ-C30 and CR-29 EORTC questionnaires.	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026